Abstract
BACKGROUND: Prostatic cancer is the 6th commonest cancer worldwide, and the 2nd commonest cancer among men. In Iraq, it is the fourth most common cancer and cause of cancer deaths in males. The commonest form of prostatic cancer is adenocarcinoma (75% of patients > 65 years). Prevalence of prostate cancer rises with age and hormonal causes. Core needle biopsy is a standard technique and largely preferred for non-operative diagnosis since it permits architectural and cytological assessment. OBJECTIVE: Immunohistochemical evaluation of CD44 expression in prostatic adenocarcinoma as a proliferative marker and correlate it with clinicopathological parameters (age, PSA level, and tumor grade). MATERIALS AND METHODS: Prostatic specimens were obtained via different procedures (TURP, and tru-cut biopsy). Formalin fixed paraffin embedded blocks from 50 patients with prostatic adenocarcinoma, histological sections taken for hematoxylin and eosin staining to determine histopathological features, monoclonal antibody for CD44 used for immunohistochemical staining of tissue sections and CD44 expression correlated with clinicopathological parameters (age, PSA level, and tumor grade). RESULTS: There was a significant inverse correlation between CD44 expression and Gleason grade score (i.e. high expression in low grade tumors), while there was no correlation between age and PSA level with CD44 expression. CONCLUSION: CD44 expression in prostatic adenocarcinoma can be utilized as a prognostic marker as it implies less tumor aggressiveness with positive high expression which means lower grade tumor and better differentiation.
Recommended Citation
Imran, Wurood; Almosawi, Hadi; and Husseini, Rafid Al
(2020)
"Clinicopathological Evaluation of CD44 Expression as a Proliferative Marker in Prostatic Adenocarcinoma,"
Iraqi Postgraduate Medical Journal: Vol. 20:
Iss.
2, Article 10.
DOI: 10.52573/ipmj.2020.168625
Available at:
https://www.ipmj.org/journal/vol20/iss2/10
DOI
10.52573/ipmj.2020.168625